Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
5.37M
-
Number of holders
-
9
-
Total 13F shares, excl. options
-
178K
-
Shares change
-
+14.8K
-
Total reported value, excl. options
-
$1.26M
-
Value change
-
+$105K
-
Number of buys
-
3
-
Number of sells
-
-2
-
Price
-
$7.10
Significant Holders of Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP) as of Q2 2025
9 filings reported holding NEUP - Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share as of Q2 2025.
Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP) has 9 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 178K shares
of 5.37M outstanding shares and own 3.31% of the company stock.
Largest 9 shareholders include AdvisorShares Investments LLC (67.7K shares), Lynx1 Capital Management LP (45.8K shares), Prosperity Wealth Management, Inc. (29.8K shares), CITADEL ADVISORS LLC (14.6K shares), Merck & Co., Inc. (10K shares), Cyndeo Wealth Partners, LLC (10K shares), RHUMBLINE ADVISERS (33 shares), MORGAN STANLEY (7 shares), and BANK OF AMERICA CORP /DE/ (1 shares).
This table shows the top 9 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.